Your browser doesn't support javascript.
loading
High-throughput screening for a SARS-CoV-2 frameshifting inhibitor using a cell-free protein synthesis system.
Machida, Kodai; Tanaka, Rin; Miki, Seraya; Noseda, Shotaro; Yuasa-Sunagawa, Mayumi; Imataka, Hiroaki.
Afiliação
  • Machida K; Department of Applied Chemistry, Graduate School of Engineering, University of Hyogo, Himeji, 671-2201, Japan.
  • Tanaka R; Department of Applied Chemistry, Graduate School of Engineering, University of Hyogo, Himeji, 671-2201, Japan.
  • Miki S; Department of Applied Chemistry, Graduate School of Engineering, University of Hyogo, Himeji, 671-2201, Japan.
  • Noseda S; Department of Applied Chemistry, Graduate School of Engineering, University of Hyogo, Himeji, 671-2201, Japan.
  • Yuasa-Sunagawa M; Department of Applied Chemistry, Graduate School of Engineering, University of Hyogo, Himeji, 671-2201, Japan.
  • Imataka H; Department of Applied Chemistry, Graduate School of Engineering, University of Hyogo, Himeji, 671-2201, Japan.
Biotechniques ; 76(4): 161-168, 2024 Apr.
Article em En | MEDLINE | ID: mdl-38293767
ABSTRACT
Programmed-1 ribosomal frameshifting (-1 PRF) is a translational mechanism adopted by some viruses, including SARS-CoV-2. To find a compound that can inhibit -1 PRF in SARS-CoV-2, we set up a high-throughput screening system using a HeLa cell extract-derived cell-free protein synthesis (CFPS) system. A total of 32,000 compounds were individually incubated with the CFPS system programmed with a -1 PRF-EGFP template. Several compounds were observed to decrease the -1 PRF-driven fluorescence, and one of them had some suppressive effect on -1 PRF of a SARS-CoV-2 genome sequence in transfected cells. Thus the CFPS system can be used as a tool for a high-throughput screening of chemicals.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: SARS-CoV-2 / COVID-19 Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: SARS-CoV-2 / COVID-19 Idioma: En Ano de publicação: 2024 Tipo de documento: Article